A detailed history of Cibc Private Wealth Group, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cibc Private Wealth Group, LLC holds 3,929 shares of HALO stock, worth $244,855. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,929
Previous 2,883 36.28%
Holding current value
$244,855
Previous $117,000 75.21%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$37.81 - $52.4 $39,549 - $54,810
1,046 Added 36.28%
3,929 $205,000
Q1 2024

May 10, 2024

BUY
$33.68 - $41.95 $97,099 - $120,941
2,883 New
2,883 $117,000
Q4 2022

Jun 01, 2023

BUY
$40.06 - $59.44 $1.05 Million - $1.56 Million
26,239 New
26,239 $1.49 Million
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $1.05 Million - $1.56 Million
26,239 New
26,239 $1.49 Million
Q4 2019

Jan 30, 2020

SELL
$14.93 - $19.53 $324,324 - $424,250
-21,723 Closed
0 $0
Q2 2019

Jul 31, 2019

SELL
$14.75 - $17.26 $91,627 - $107,219
-6,212 Reduced 22.24%
21,723 $373,000
Q1 2019

May 10, 2019

SELL
$13.94 - $17.58 $59,077 - $74,504
-4,238 Reduced 13.17%
27,935 $450,000
Q4 2018

Feb 05, 2019

BUY
$13.33 - $18.66 $25,873 - $36,219
1,941 Added 6.42%
32,173 $470,000
Q3 2018

Nov 14, 2018

BUY
$16.68 - $18.41 $74,492 - $82,219
4,466 Added 17.33%
30,232 $549,000
Q2 2018

Aug 02, 2018

BUY
$16.87 - $20.3 $59,736 - $71,882
3,541 Added 15.93%
25,766 $435,000
Q1 2018

May 17, 2018

SELL
$17.06 - $21.2 $9,826 - $12,211
-576 Reduced 2.53%
22,225 $435,000
Q4 2017

Feb 12, 2018

SELL
$16.75 - $20.8 $48,859 - $60,673
-2,917 Reduced 11.34%
22,801 $462,000
Q3 2017

Nov 14, 2017

SELL
$11.76 - $17.4 $10,666 - $15,781
-907 Reduced 3.41%
25,718 $447,000
Q2 2017

Aug 09, 2017

BUY
N/A
26,625
26,625 $341,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.68B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Cibc Private Wealth Group, LLC Portfolio

Follow Cibc Private Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.